BETHESDA, Md., Sept. 21 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented first interim data from a phase 1 dose-escalation clinical study for BiTE antibody MT110, the first T-cell engaging antibody for the treatment of solid tumors. The interim data(1) were presented at the Multidisciplinary Congress of the European Cancer Organisation (ECCO) and 34th meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany. MT110 is designed to direct the patients’ own T cells against cancer cells that express the epithelial cell adhesion molecule (EpCAM).
“We are very encouraged by the tolerability of MT110 observed in this heavily pre-treated population of cancer patients and look forward to updating our results as we continue to increase the dose,” commented Prof. Walter Fiedler from the University Hospital of Hamburg-Eppendorf, Germany, and principal investigator of the study.
MT110 is the second BiTE antibody undergoing clinical investigation. Micromet also has ongoing trials for blinatumomab (MT103), including a phase 2 trial for acute lymphoblastic leukemia (ALL) and a phase 1 trial for non-Hodgkin’s lymphoma.
About BiTE Antibodies
About Micromet, Inc.
Forward-Looking Statements
SOURCE Micromet, Inc.
CONTACT: US Media, Andrea tenBroek/Chris Stamm, +1-781-684-0770,
micromet@schwartz-pr.com, or European Media, Ludger Wess, +49(40)8816-5964,
ludger@akampion.com, or US Investors, Susan Noonan, +1-212-966-3650,
susan@sanoonan.com, or European Investors, Ines-Regina Buth,
+49(30)2363-2768, ines@akampion.com
Web site: http://www.micromet-inc.com/
